The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Epigenetic modifications as therapeutic targets
Open accessAbstract
Epigenetic modifications work in concert with genetic mechanisms to regulate transcriptional activity in normal tissues and are often dysregulated in disease. Although they are somatically heritable, modifications of DNA and histones are also reversible, making them good targets for therapeutic intervention. Epigenetic changes often precede disease pathology, making them valuable diagnostic indicators for disease risk or prognostic indicators for disease progression. Several inhibitors of histone deacetylation or DNA methylation are approved for hematological malignancies by the US Food and Drug Administration and have been in clinical use for several years. More recently, histone methylation and microRNA expression have gained attention as potential therapeutic targets. The presence of multiple epigenetic aberrations within malignant tissue and the abilities of cells to develop resistance suggest that epigenetic therapies are most beneficial when combined with other anticancer strategies, such as signal transduction inhibitors or cytotoxic treatments. A key challenge for future epigenetic therapies will be to develop inhibitors with specificity to particular regions of chromosomes, thereby potentially reducing side effects.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
MicroRNA signatures in human cancers
Calin, G. A., & Croce, C. M. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1997 · Cited by 7,590
Conversion of 5-Methylcytosine to 5-Hydroxymethylcytosine in Mammalian DNA by MLL Partner TET1
Tahiliani, M., Koh, K. P., Shen, Y., Pastor, W. A., Bandukwala, H., Brudno, Y., Agarwal, S., Iyer, L. M., Liu, D. R., Aravind, L., et al. (2009) · Science · doi:10.1126/science.1170116 · Cited by 5,836
Human DNA methylomes at base resolution show widespread epigenomic differences
Lister, R., Pelizzola, M., Dowen, R. H., Hawkins, R. D., Hon, G., Tonti-Filippini, J., Nery, J. R., Lee, L., Ye, Z., Ngo, Q.-M., et al. (2009) · Nature · doi:10.1038/nature08514 · Cited by 4,673
Jones, P. A., & Baylin, S. B. (2007) · Cell · doi:10.1016/j.cell.2007.01.029 · Cited by 4,515
Self-citationLysine acetylation targets protein complexes and co-regulates major cellular functions
Choudhary, C., Kumar, C., Gnad, F., Nielsen, M. L., Rehman, M., Walther, T. C., Olsen, J. V., & Mann, M. (2009) · Science · doi:10.1126/science.1175371 · Cited by 4,040
Epigenetics in human disease and prospects for epigenetic therapy
Egger, G., Liang, G., Aparicio, A., & Jones, P. A. (2004) · Nature · doi:10.1038/nature02625 · Cited by 3,232
Self-citationUnique microRNA molecular profiles in lung cancer diagnosis and prognosis
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R. M., Okamoto, A., Yokota, J., Tanaka, T., et al. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.01.025 · Cited by 3,023
Causes and consequences of microRNA dysregulation in cancer
Croce, C. M. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2634 · Cited by 2,998
Epigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Fenaux, P., Mufti, G. J., Hellstrom-Lindberg, E., Santini, V., Finelli, C., Giagounidis, A., Schoch, R., Gattermann, N., Sanz, G., List, A., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70003-8 · Cited by 2,663 · cited 1×
“5-Azacytidine (5-Aza-CR; Vidaza; azacitidine), a nucleoside analog that is incorporated into RNA and DNA, is approved to treat patients with high-risk myelodysplastic syndromes (MDS) and successful clinical results have recently been reported ( Tables 2 and 3”
BackgroundSharma, S., Kelly, T. K., & Jones, P. A. (2010) · Carcinogenesis · doi:10.1093/carcin/bgp220 · Cited by 2,637
Self-citationCpG island methylator phenotype in colorectal cancer
Toyota, M., Ahuja, N., Ohe-Toyota, M., Herman, J. G., Baylin, S. B., & Issa, J.-P. J. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.15.8681 · Cited by 2,523
Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma
Noushmehr, H., Weisenberger, D. J., Diefes, K., Phillips, H. S., Pujara, K., Berman, B. P., Pan, F., Pelloski, C. E., Sulman, E. P., Bhat, K. P., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.017 · Cited by 2,337
Irizarry, R. A., Ladd-Acosta, C., Wen, B., Wu, Z., Montano, C., Onyango, P., Cui, H., Gabo, K., Rongione, M., Webster, M., et al. (2009) · Nature Genetics · doi:10.1038/ng.298 · Cited by 2,177
The NIH Roadmap Epigenomics Mapping Consortium
Bernstein, B. E., Stamatoyannopoulos, J. A., Costello, J. F., Ren, B., Milosavljevic, A., Meissner, A., Kellis, M., Marra, M. A., Beaudet, A. L., Ecker, J. R., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1045 · Cited by 1,892
Cameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
LSD1 demethylates repressive histone marks to promote androgen-receptor-dependent transcription
Metzger, E., Wissmann, M., Yin, N., Müller, J. M., Schneider, R., Peters, A. H. F. M., Günther, T., Buettner, R., & Schüle, R. (2005) · Nature · doi:10.1038/nature04020 · Cited by 1,733
Fabbri, M., Garzon, R., Cimmino, A., Liu, Z., Zanesi, N., Callegari, E., Liu, S., Alder, H., Costinean, S., Fernandez-Cymering, C., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0707628104 · Cited by 1,673
HDAC2 negatively regulates memory formation and synaptic plasticity
Guan, J.-S., Haggarty, S. J., Giacometti, E., Dannenberg, J.-H., Joseph, N., Gao, J., Nieland, T. J. F., Zhou, Y., Wang, X., Mazitschek, R., et al. (2009) · Nature · doi:10.1038/nature07925 · Cited by 1,644
Epigenetic gene silencing in cancer – a mechanism for early oncogenic pathway addiction?
Baylin, S. B., & Ohm, J. E. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1799 · Cited by 1,639
Therapeutic silencing of microRNA-122 in primates with chronic hepatitis C virus infection
Lanford, R. E., Hildebrandt-Eriksen, E. S., Petri, A., Persson, R., Lindow, M., Munk, M. E., Kauppinen, S., & Ørum, H. (2010) · Science · doi:10.1126/science.1178178 · Cited by 1,459
Therapeutic microRNA Delivery Suppresses Tumorigenesis in a Murine Liver Cancer Model
Kota, J., Chivukula, R. R., O'Donnell, K. A., Wentzel, E. A., Montgomery, C. L., Hwang, H.-W., Chang, T.-C., Vivekanandan, P., Torbenson, M., Clark, K. R., et al. (2009) · Cell · doi:10.1016/j.cell.2009.04.021 · Cited by 1,452
Saito, Y., Liang, G., Egger, G., Friedman, J. M., Chuang, J. C., Coetzee, G. A., & Jones, P. A. (2006) · Cancer Cell · doi:10.1016/j.ccr.2006.04.020 · Cited by 1,335
Self-citationEpigenetic therapy of cancer: past, present and future
Yoo, C. B., & Jones, P. A. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd1930 · Cited by 1,289
Self-citationRecovery of learning and memory is associated with chromatin remodelling
Fischer, A., Sananbenesi, F., Wang, X., Dobbin, M., & Tsai, L.-H. (2007) · Nature · doi:10.1038/nature05772 · Cited by 1,227
Schlesinger, Y., Straussman, R., Keshet, I., Farkash, S., Hecht, M., Zimmerman, J., Eden, E., Yakhini, Z., Ben-Shushan, E., Reubinoff, B. E., et al. (2007) · Nature Genetics · doi:10.1038/ng1950 · Cited by 1,226
Epigenetic stem cell signature in cancer
Widschwendter, M., Fiegl, H., Egle, D., Mueller-Holzner, E., Spizzo, G., Marth, C., Weisenberger, D. J., Campan, M., Young, J., Jacobs, I., et al. (2007) · Nature Genetics · doi:10.1038/ng1941 · Cited by 1,143
Ohm, J. E., McGarvey, K. M., Yu, X., Cheng, L., Schuebel, K. E., Cope, L., Mohammad, H. P., Chen, W., Daniel, V. C., Yu, W., et al. (2007) · Nature Genetics · doi:10.1038/ng1972 · Cited by 1,130
Global histone modification patterns predict risk of prostate cancer recurrence
Seligson, D. B., Horvath, S., Shi, T., Yu, H., Tze, S., Grunstein, M., & Kurdistani, S. K. (2005) · Nature · doi:10.1038/nature03672 · Cited by 1,092
A microRNA DNA methylation signature for human cancer metastasis
Lujambio, A., Calin, G. A., Villanueva, A., Ropero, S., Sánchez-Céspedes, M., Blanco, D., Montuenga, L. M., Rossi, S., Nicoloso, M. S., Faller, W. J., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0803055105 · Cited by 1,078
Haggarty, S. J., Koeller, K. M., Wong, J. C., Grozinger, C. M., & Schreiber, S. L. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0430973100 · Cited by 1,066
Active DNA demethylation: many roads lead to Rome
Wu, S. C., & Zhang, Y. (2010) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2950 · Cited by 1,060
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Varambally, S., Cao, Q., Mani, R.-S., Shankar, S., Wang, X., Ateeq, B., Laxman, B., Cao, X., Jing, X., Ramnarayanan, K., et al. (2008) · Science · doi:10.1126/science.1165395 · Cited by 1,052
Inactivation of the apoptosis effector Apaf-1 in malignant melanoma
Soengas, M. S., Capodieci, P., Polsky, D., Mora, J., Esteller, M., Opitz-Araya, X., McCombie, R., Herman, J. G., Gerald, W. L., Lazebnik, Y. A., et al. (2001) · Nature · doi:10.1038/35051606 · Cited by 966
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Tan, J., Yang, X., Zhuang, L., Jiang, X., Chen, W., Lee, P. L., Karuturi, R. K. M., Tan, P. B. O., Liu, E. T., & Yu, Q. (2007) · Genes & Development · doi:10.1101/gad.1524107 · Cited by 895 · cited 1×
“DZNep depletes cellular levels of PRC2 components (EZH2, EED and SUZ12) and consequently reduces H3K27me3 levels and induces apoptosis in breast cancer, but not normal, cell”
BackgroundHistone Deacetylase Inhibitors in Cancer Therapy
Lane, A. A., & Chabner, B. A. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.1291 · Cited by 874
Reversal of H3K9me2 by a Small-Molecule Inhibitor for the G9a Histone Methyltransferase
Kubicek, S., O'Sullivan, R. J., August, E. M., Hickey, E. R., Zhang, Q., Teodoro, M. L., Rea, S., Mechtler, K., Kowalski, J. A., Homon, C. A., et al. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.01.017 · Cited by 859
Self-citationBachmann, I. M., Halvorsen, O. J., Collett, K., Stefansson, I. M., Straume, O., Haukaas, S. A., Salvesen, H. B., Otte, A. P., & Akslen, L. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.01.5180 · Cited by 851
Yu, J., Yu, J., Mani, R.-S., Cao, Q., Brenner, C. J., Cao, X., Wang, X., Wu, L., Li, J., Hu, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.03.018 · Cited by 850
DNA Methylation Signatures Identify Biologically Distinct Subtypes in Acute Myeloid Leukemia
Figueroa, M. E., Lugthart, S., Li, Y., Erpelinck-Verschueren, C., Deng, X., Christos, P. J., Schifano, E., Booth, J., van Putten, W., Skrabanek, L., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2009.11.020 · Cited by 833
Drug development of MET inhibitors: targeting oncogene addiction and expedience
Comoglio, P. M., Giordano, S., & Trusolino, L. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2530 · Cited by 818
The lysine demethylase LSD1 (KDM1) is required for maintenance of global DNA methylation
Wang, J., Hevi, S., Kurash, J. K., Lei, H., Gay, F., Bajko, J., Su, H., Sun, W., Chang, H., Xu, G., et al. (2009) · Nature Genetics · doi:10.1038/ng.268 · Cited by 815
MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Weller, M., Stupp, R., Reifenberger, G., Brandes, A. A., van den Bent, M. J., Wick, W., & Hegi, M. E. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2009.197 · Cited by 778
The putative oncogene GASC1 demethylates tri- and dimethylated lysine 9 on histone H3
Cloos, P. A. C., Christensen, J., Agger, K., Maiolica, A., Rappsilber, J., Antal, T., Hansen, K. H., & Helin, K. (2006) · Nature · doi:10.1038/nature04837 · Cited by 736
Javierre, B. M., Fernandez, A. F., Richter, J., Al-Shahrour, F., Martin-Subero, J. I., Rodriguez-Ubreva, J., Berdasco, M., Fraga, M. F., O'Hanlon, T. P., Rider, L. G., et al. (2010) · Genome Research · doi:10.1101/gr.100289.109 · Cited by 668
Histone lysine demethylases: emerging roles in development, physiology and disease
Shi, Y. (2007) · Nature Reviews Genetics · doi:10.1038/nrg2218 · Cited by 601
Miranda, T. B., Cortez, C. C., Yoo, C. B., Liang, G., Abe, M., Kelly, T. K., Marquez, V. E., & Jones, P. A. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0013 · Cited by 596
Self-citationEpigenetic mechanisms in neurological diseases: genes, syndromes, and therapies
Urdinguio, R. G., Sanchez-Mut, J. V., & Esteller, M. (2009) · The Lancet Neurology · doi:10.1016/s1474-4422(09)70262-5 · Cited by 582
Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer
Shen, L., Toyota, M., Kondo, Y., Lin, E., Zhang, L., Guo, Y., Hernandez, N. S., Chen, X., Ahmed, S., Konishi, K., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0704652104 · Cited by 559
Silverman, L. R., McKenzie, D. R., Peterson, B. L., Holland, J. F., Backstrom, J. T., Beach, C. L., & Larson, R. A. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.05.4346 · Cited by 552
Akt-Mediated Phosphorylation of EZH2 Suppresses Methylation of Lysine 27 in Histone H3
Cha, T.-L., Zhou, B. P., Xia, W., Wu, Y., Yang, C.-C., Chen, C.-T., Ping, B., Otte, A. P., & Hung, M.-C. (2005) · Science · doi:10.1126/science.1118947 · Cited by 548
Distinct genetic profiles in colorectal tumors with or without the CpG island methylator phenotype
Toyota, M., Ohe-Toyota, M., Ahuja, N., & Issa, J.-P. J. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.2.710 · Cited by 473
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Balasubramanian, S., Ramos, J., Luo, W., Sirisawad, M., Verner, E., & Buggy, J. J. (2008) · Leukemia · doi:10.1038/leu.2008.9 · Cited by 458
Issa, J.-P. J., & Kantarjian, H. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2783 · Cited by 446
Schulte, J. H., Lim, S., Schramm, A., Friedrichs, N., Koster, J., Versteeg, R., Ora, I., Pajtler, K., Klein-Hitpass, L., Kuhfittig-Kulle, S., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-1735 · Cited by 445
Soriano, A. O., Yang, H., Faderl, S., Estrov, Z., Giles, F., Ravandi, F., Cortes, J., Wierda, W. G., Ouzounian, S., Quezada, A., et al. (2007) · Blood · doi:10.1182/blood-2007-03-078576 · Cited by 390
G9a and Glp Methylate Lysine 373 in the Tumor Suppressor p53
Huang, J., Dorsey, J., Chuikov, S., Zhang, X., Jenuwein, T., Reinberg, D., & Berger, S. L. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.062588 · Cited by 383
Friedman, J. M., Liang, G., Liu, C.-C., Wolff, E. M., Tsai, Y. C., Ye, W., Zhou, X., & Jones, P. A. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-3114 · Cited by 382
Self-citationGal-Yam, E. N., Egger, G., Iniguez, L., Holster, H., Einarsson, S., Zhang, X., Lin, J. C., Liang, G., Jones, P. A., & Tanay, A. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806437105 · Cited by 380
Self-citationEpigenetic modifications in pluripotent and differentiated cells
Meissner, A. (2010) · Nature Biotechnology · doi:10.1038/nbt.1684 · Cited by 372
Fiskus, W., Wang, Y., Sreekumar, A., Buckley, K. M., Shi, H., Jillella, A., Ustun, C., Rao, R., Fernandez, P., Chen, J., et al. (2009) · Blood · doi:10.1182/blood-2009-03-213496 · Cited by 356
Strathdee, G., MacKean, M. J., Illand, M., & Brown, R. (1999) · Oncogene · doi:10.1038/sj.onc.1202540 · Cited by 350
Expression profile of class I histone deacetylases in human cancer tissues
Nakagawa, M., Oda, Y., Eguchi, T., Aishima, S.-I., Yao, T., Hosoi, F., Basaki, Y., Ono, M., Kuwano, M., Tanaka, M., et al. (2007) · Oncology Reports · doi:10.3892/or.18.4.769 · Cited by 341
Preferential response of cancer cells to zebularine
Cheng, J. C., Yoo, C. B., Weisenberger, D. J., Chuang, J., Wozniak, C., Liang, G., Marquez, V. E., Greer, S., Orntoft, T. F., Thykjaer, T., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.06.023 · Cited by 319
Self-citationLeukaemogenesis: more than mutant genes
Chen, J., Odenike, O., & Rowley, J. D. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2765 · Cited by 311
Wolff, E. M., Byun, H.-M., Han, H. F., Sharma, S., Nichols, P. W., Siegmund, K. D., Yang, A. S., Jones, P. A., & Liang, G. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000917 · Cited by 308
Self-citationStructural basis for G9a-like protein lysine methyltransferase inhibition by BIX-01294
Chang, Y., Zhang, X., Horton, J. R., Upadhyay, A. K., Spannhoff, A., Liu, J., Snyder, J. P., Bedford, M. T., & Cheng, X. (2009) · Nature Structural & Molecular Biology · doi:10.1038/nsmb.1560 · Cited by 308
The role of epigenetics in the pathology of diabetic complications
Villeneuve, L. M., & Natarajan, R. (2010) · American Journal of Physiology-Renal Physiology · doi:10.1152/ajprenal.00200.2010 · Cited by 295
The emerging field of dynamic lysine methylation of non-histone proteins
Huang, J., & Berger, S. L. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.01.012 · Cited by 290
MicroRNA-143 targets DNA methyltransferases 3A in colorectal cancer
Ng, E. K. O., Tsang, W. P., Ng, S. S. M., Jin, H. C., Yu, J., Li, J. J., Röcken, C., Ebert, M. P. A., Kwok, T. T., & Sung, J. J. Y. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605195 · Cited by 284
Fandy, T. E., Herman, J. G., Kerns, P., Jiemjit, A., Sugar, E. A., Choi, S.-H., Yang, A. S., Aucott, T., Dauses, T., Odchimar-Reissig, R., et al. (2009) · Blood · doi:10.1182/blood-2009-02-203547 · Cited by 282
Ramalingam, S. S., Maitland, M. L., Frankel, P., Argiris, A. E., Koczywas, M., Gitlitz, B., Thomas, S., Espinoza-Delgado, I., Vokes, E. E., Gandara, D. R., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.9094 · Cited by 273
van Rijnsoever, M., Elsaleh, H., Joseph, D. J., McCaul, K. A., & Iacopetta, B. J. (2003) · PubMed · Cited by 267
Understanding microRNAs in neurodegeneration
Eacker, S. M., Dawson, T. M., & Dawson, V. L. (2009) · Nature Reviews Neuroscience · doi:10.1038/nrn2726 · Cited by 239
Kondo, Y., Shen, L., Ahmed, S., Boumber, Y., Sekido, Y., Haddad, B. R., & Issa, J.-P. J. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002037 · Cited by 234
Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia
Garcia-Manero, G., Assouline, S., Cortes, J., Estrov, Z., Kantarjian, H., Yang, H., Newsome, W. M., Miller, W. H., Rousseau, C., Kalita, A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-115873 · Cited by 233
Histone Deacetylase Inhibitors: Current Status and Overview of Recent Clinical Trials
Ma, X., Ezzeldin, H. H., & Diasio, R. B. (2009) · Drugs · doi:10.2165/11315680-000000000-00000 · Cited by 227
Global levels of histone modifications predict prostate cancer recurrence
Ellinger, J., Kahl, P., von der Gathen, J., Rogenhofer, S., Heukamp, L. C., Gütgemann, I., Walter, B., Hofstädter, F., Büttner, R., Müller, S. C., et al. (2010) · The Prostate · doi:10.1002/pros.21038 · Cited by 220
Delivery of 5-Aza-2′-Deoxycytidine to Cells Using Oligodeoxynucleotides
Yoo, C. B., Jeong, S., Egger, G., Liang, G., Phiasivongsa, P., Tang, C., Redkar, S., & Jones, P. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0251 · Cited by 219
Self-citationMinireview: Protein Arginine Methylation of Nonhistone Proteins in Transcriptional Regulation
Lee, Y.-H., & Stallcup, M. R. (2009) · Molecular Endocrinology · doi:10.1210/me.2008-0380 · Cited by 211
Berdasco, M., Ropero, S., Setien, F., Fraga, M. F., Lapunzina, P., Losson, R., Alaminos, M., Cheung, N.-K., Rahman, N., & Esteller, M. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0906831106 · Cited by 206
CpG Island Methylator Phenotype Predicts Progression of Malignant Melanoma
Tanemura, A., Terando, A. M., Sim, M.-S., van Hoesel, A. Q., de Maat, M. F. G., Morton, D. L., & Hoon, D. S. B. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1361 · Cited by 206
Marango, J., Shimoyama, M., Nishio, H., Meyer, J. A., Min, D.-J., Sirulnik, A., Martinez-Martinez, Y., Chesi, M., Bergsagel, P. L., Zhou, M.-M., et al. (2008) · Blood · doi:10.1182/blood-2007-06-092122 · Cited by 197
Huang, Y., Stewart, T. M., Wu, Y., Baylin, S. B., Marton, L. J., Perkins, B., Jones, R. J., Woster, P. M., & Casero, R. A. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1293 · Cited by 194
Ramalingam, S. S., Parise, R. A., Ramananthan, R. K., Lagattuta, T. F., Musguire, L. A., Stoller, R. G., Potter, D. M., Argiris, A. E., Zwiebel, J. A., Egorin, M. J., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0162 · Cited by 193
Zebularine: a new drug for epigenetic therapy
Yoo, C. B., Cheng, J. C., & Jones, P. A. (2004) · Biochemical Society Transactions · doi:10.1042/bst0320910 · Cited by 191
Self-citationThe Role of DNA Methylation in the Central Nervous System and Neuropsychiatric Disorders
Feng, J., & Fan, G. (2009) · International Review of Neurobiology · doi:10.1016/s0074-7742(09)89004-1 · Cited by 175
Munster, P. N., Marchion, D., Thomas, S., Egorin, M., Minton, S., Springett, G., Lee, J.-H., Simon, G., Chiappori, A., Sullivan, D., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605293 · Cited by 167
Epigenetics and Complex Disease: From Etiology to New Therapeutics
Ptak, C., & Petronis, A. (2008) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev.pharmtox.48.113006.094731 · Cited by 167
Braiteh, F., Soriano, A. O., Garcia-Manero, G., Hong, D., Johnson, M. M., Silva, L. D. P., Yang, H., Alexander, S., Wolff, J., & Kurzrock, R. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1247 · Cited by 164
Minireview: Epigenetic Changes in Ovarian Cancer
Balch, C., Fang, F., Matei, D. E., Huang, T. H. ‐., & Nephew, K. P. (2009) · Endocrinology · doi:10.1210/en.2009-0404 · Cited by 146
Bruserud, Ø., Stapnes, C., Ersvær, E., Gjertsen, B. T., & Ryningen, A. (2007) · Current Pharmaceutical Biotechnology · doi:10.2174/138920107783018417 · Cited by 141
de Cáceres, I. I., Cortés-Sempere, M., Moratilla, C., Machado-Pinilla, R., Rodríguez‐Fanjul, V., Manguán-García, C., Cejas, P., López‐Ríos, F., Paz-Ares, L. G., de CastroCarpeño, J., et al. (2009) · Oncogene · doi:10.1038/onc.2009.454 · Cited by 140
Histone Deacetylation: An Important Mechanism in Inflammatory Lung Diseases
Adcock, I. M., Ito, K., & Barnes, P. J. (2005) · COPD Journal of Chronic Obstructive Pulmonary Disease · doi:10.1080/15412550500346683 · Cited by 136
Genome‐wide DNA methylation profiles in precancerous conditions and cancers
Kanai, Y. (2009) · Cancer Science · doi:10.1111/j.1349-7006.2009.01383.x · Cited by 122
Drug Sensitivity Prediction by CpG Island Methylation Profile in the NCI-60 Cancer Cell Line Panel
Shen, L., Kondo, Y., Ahmed, S., Boumber, Y., Konishi, K., Guo, Y., Chen, X., Vilaythong, J. N., & Issa, J. J. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-1502 · Cited by 122
Siu, L. L., Пили, Р., Durán, I., Messersmith, W. A., Chen, E. X., Sullivan, R., MacLean, M., King, S., Brown, S., Reid, G. K., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.5730 · Cited by 119
Kantarjian, H. M., O'Brien, S. M., Shan, J., Aribi, A. M., Garcia‐Manero, G., Jabbour, E. J., Ravandi, F., Cortes, J. E., Davisson, J., & Issa, J. J. (2006) · Cancer · doi:10.1002/cncr.22376 · Cited by 115
Requirement of Histone Methyltransferase SMYD3 for Estrogen Receptor-mediated Transcription
Kim, H., Heo, K., Kim, J. H., Kim, K., Choi, J., & An, W. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.021485 · Cited by 113
McCaffrey, A. P., Fawcett, P., Nakai, H., McCaffrey, R. L., Ehrhardt, A., Pham, T.-T. T., Pandey, K., Xu, H., Feuss, S., Storm, T. A., et al. (2008) · Molecular Therapy · doi:10.1038/mt.2008.37 · Cited by 112
Voso, M. T., Santini, V., Finelli, C., Musto, P., Pogliani, E., Angelucci, E., Fioritoni, G., Alimena, G., Maurillo, L., Cortelezzi, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0494 · Cited by 102
Histone deacetylase inhibitors in lymphoma and solid malignancies
Rasheed, W. K., Bishton, M. J., Johnstone, R. W., & Prince, H. M. (2008) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.8.3.413 · Cited by 102
Gore, S. D., Weng, L. J., Zhai, S., et al. (2001) · PubMed · Cited by 102
Mohammad, H. P., Cai, Y., McGarvey, K. M., Easwaran, H., Neste, L. V., Ohm, J. E., O’Hagan, H. M., & Baylin, S. B. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0065 · Cited by 96
Current status of epigenetic treatment in myelodysplastic syndromes
Kuendgen, A., & Lübbert, M. (2008) · Annals of Hematology · doi:10.1007/s00277-008-0477-9 · Cited by 93
Tackling the epigenome: challenges and opportunities for collaboration
Satterlee, J. S., Schübeler, D., & Ng, H. (2010) · Nature Biotechnology · doi:10.1038/nbt1010-1039 · Cited by 89
Wargo, J. A., Robbins, P. F., Li, Y., Zhao, Y., El‐Gamil, M., Caragacianu, D. L., Zheng, Z., Hong, J. A., Downey, S. G., Schrump, D. S., et al. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0562-x · Cited by 88
Lin, J., Gilbert, J., Rudek, M. A., Zwiebel, J. A., Gore, S. D., Jiemjit, A., Zhao, M., Baker, S. D., Ambinder, R. F., Herman, J. G., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0567 · Cited by 83
DNA Methylation as a Biomarker in Breast Cancer
Martens, J. W. M., Margossian, A. L., Schmitt, M., Foekens, J. A., & Harbeck, N. (2009) · Future Oncology · doi:10.2217/fon.09.89 · Cited by 81
Oka (2009) · International Journal of Oncology · doi:10.3892/ijo_00000366 · Cited by 71
Epigenetic mechanisms of irinotecan sensitivity in colorectal cancer cell lines
Crea, F., Giovannetti, E., Cortesi, F., Mey, V., Nannizzi, S., Ruiz, M. I. G., Ricciardi, S., Tacca, M. D., Peters, G. J., & Danesi, R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0027 · Cited by 41
Lall, S. (2007) · Nature Structural & Molecular Biology · doi:10.1038/nsmb1107-1110 · Cited by 38
β-adrenergic receptor induction in HeLa cells: Synergistic effect of 5-azacytidine and butyrate
Jahangeer, S. M., Elliott, R. M., & Henneberry, R. C. (1982) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(82)80067-3 · Cited by 33
Epigenetics of Neurological Cancers
Fouse, S. D., & Costello, J. (2009) · Future Oncology · doi:10.2217/fon.09.132 · Cited by 30
Cited by
Shrestha, S., & Offer, S. M. (2016) · Medical Epigenetics · doi:10.1159/000444713 · Cited by 8,914
A decade of exploring the cancer epigenome—biological and translational implications
Baylin, S. B., & Jones, P. A. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3130 · Cited by 2,871
Self-citationEpigenetic modifications and human disease
Portela, A., & Esteller, M. (2010) · Nature Biotechnology · doi:10.1038/nbt.1685 · Cited by 2,836
Roulois, D., Loo Yau, H., Singhania, R., Wang, Y., Danesh, A., Shen, S. Y., Han, H., Liang, G., Jones, P. A., Pugh, T. J., et al. (2015) · Cell · doi:10.1016/j.cell.2015.07.056 · Cited by 1,527
Self-citationEpigenetic protein families: a new frontier for drug discovery
Arrowsmith, C. H., Bountra, C., Fish, P. V., Lee, K., & Schapira, M. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3674 · Cited by 1,327
Metadata
- Authors
- Kelly, T. K., De Carvalho, D. D., & Jones, P. A.
- Venue
- Nature Biotechnology
- Published
- 2010-10
- Volume
- 28
- Issue
- 10
- Pages
- 1069-1078
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2089626640
- Cited by
- 793
- References
- 116
- FWCI
- 24.34
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.